

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Hansoh Pharmaceutical Group Company Limited

翰森製藥集團有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 3692)

VOLUNTARY ANNOUNCEMENT

BIOLOGICS LICENSE APPLICATION OF RISVUTATUG REZETECAN FOR INJECTION (HS-20093) FOR OSTEOSARCOMA ACCEPTED BY THE NMPA

The board of directors (the “**Board**”) of Hansoh Pharmaceutical Group Company Limited (the “**Company**”) and together with its subsidiaries, the “**Group**”) is pleased to announce that, on September 24, 2026, the biologics license application of the Group’s innovative medicine HS-20093 for injection (risvutatug rezetecan for injection) has been accepted by the National Medical Products Administration (the “**NMPA**”) of China, for the treatment of osteosarcoma patients aged 12 years and above who have failed at least two prior lines of therapy. HS-20093 for injection is the Group’s proprietary B7-H3 directed antibody-drug conjugate (ADC).

By Order of the Board
Hansoh Pharmaceutical Group Company Limited
Zhong Huijuan
Chairlady

Hong Kong, September 24, 2026

As at the date of this announcement, the Board comprises Ms. Zhong Huijuan as chairlady and executive director, Ms. Sun Yuan and Dr. Lyu Aifeng as executive directors, and Mr. Lin Guoqiang, Mr. Chan Charles Sheung Wai, Ms. Yang Dongtao and Mr. Yan Jia as independent non-executive directors.